Annual EBIT
-$18.01 M
-$2.75 M-18.06%
01 December 2023
Summary:
COSCIENS Biopharma annual earnings before interest & taxes is currently -$18.01 million, with the most recent change of -$2.75 million (-18.06%) on 01 December 2023. During the last 3 years, it has fallen by -$14.02 million (-351.67%).CSCI EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$5.84 M
-$3.97 M-211.90%
01 September 2024
Summary:
COSCIENS Biopharma quarterly earnings before interest & taxes is currently -$5.84 million, with the most recent change of -$3.97 million (-211.90%) on 01 September 2024. Over the past year, it has dropped by -$4.88 million (-505.70%).CSCI Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$11.53 M
-$4.88 M-73.39%
01 September 2024
Summary:
COSCIENS Biopharma TTM earnings before interest & taxes is currently -$11.53 million, with the most recent change of -$4.88 million (-73.39%) on 01 September 2024. Over the past year, it has dropped by -$9.01 million (-356.87%).CSCI TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CSCI EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -18.1% | -505.7% | -356.9% |
| 3 y3 years | -351.7% | -916.7% | -903.2% |
| 5 y5 years | -292.4% | -10000.0% | -1310.3% |
CSCI EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -291.2% | -403.2% | -299.7% |
COSCIENS Biopharma EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$5.84 M(+211.9%) | -$11.53 M(+73.4%) |
| June 2024 | - | -$1.87 M(+4.8%) | -$6.65 M(+13.7%) |
| Mar 2024 | - | -$1.79 M(-11.5%) | -$5.85 M(+33.0%) |
| Dec 2023 | -$18.01 M(+18.1%) | -$2.02 M(+109.5%) | -$4.39 M(+74.2%) |
| Sept 2023 | - | -$965.00 K(-9.9%) | -$2.52 M(+344.2%) |
| June 2023 | - | -$1.07 M(+217.2%) | -$568.10 K(-124.0%) |
| Mar 2023 | - | -$337.60 K(+125.2%) | $2.36 M(-49.0%) |
| Dec 2022 | -$15.25 M(+75.9%) | -$149.90 K(-115.1%) | $4.63 M(-19.8%) |
| Sept 2022 | - | $990.40 K(-46.7%) | $5.77 M(+5.0%) |
| June 2022 | - | $1.86 M(-3.6%) | $5.50 M(+30.4%) |
| Mar 2022 | - | $1.93 M(+93.7%) | $4.22 M(+54.6%) |
| Dec 2021 | -$8.67 M(+117.5%) | $995.40 K(+39.1%) | $2.73 M(+89.9%) |
| Sept 2021 | - | $715.70 K(+24.1%) | $1.44 M(+60.4%) |
| June 2021 | - | $576.50 K(+31.4%) | $895.00 K(-21.4%) |
| Mar 2021 | - | $438.70 K(-248.5%) | $1.14 M(-25.4%) |
| Dec 2020 | -$3.99 M(-58.2%) | -$295.50 K(-268.6%) | $1.53 M(-22.5%) |
| Sept 2020 | - | $175.30 K(-78.6%) | $1.97 M(+12.2%) |
| June 2020 | - | $820.80 K(-0.7%) | $1.76 M(+219.2%) |
| Mar 2020 | - | $826.50 K(+454.7%) | $550.40 K(-177.0%) |
| Dec 2019 | -$9.54 M(-202.0%) | $149.00 K(-478.2%) | -$714.80 K(-12.6%) |
| Sept 2019 | - | -$39.40 K(-89.8%) | -$817.50 K(-22.2%) |
| June 2019 | - | -$385.70 K(-12.1%) | -$1.05 M(+29.8%) |
| Mar 2019 | - | -$438.70 K(-1047.5%) | -$808.90 K(+26.7%) |
| Dec 2018 | $9.36 M(-146.0%) | $46.30 K(-117.0%) | -$638.60 K(-69.5%) |
| Sept 2018 | - | -$272.20 K(+88.6%) | -$2.10 M(+57.3%) |
| June 2018 | - | -$144.30 K(-46.2%) | -$1.33 M(+121.5%) |
| Mar 2018 | - | -$268.40 K(-81.0%) | -$601.90 K(+89.2%) |
| Dec 2017 | -$20.35 M(-31.0%) | -$1.41 M(-387.4%) | -$318.10 K(-124.6%) |
| Sept 2017 | - | $491.10 K(-16.3%) | $1.30 M(-13.1%) |
| June 2017 | - | $586.90 K(+3711.0%) | $1.49 M(-45.5%) |
| Mar 2017 | - | $15.40 K(-92.4%) | $2.74 M(-32.7%) |
| Dec 2016 | -$29.48 M(-15.5%) | $202.20 K(-70.6%) | $4.06 M(-27.0%) |
| Sept 2016 | - | $687.00 K(-62.5%) | $5.57 M(-1.3%) |
| June 2016 | - | $1.83 M(+36.1%) | $5.64 M(+30.0%) |
| Mar 2016 | - | $1.34 M(-21.0%) | $4.34 M(+53.2%) |
| Dec 2015 | -$34.88 M(-6.7%) | $1.70 M(+124.1%) | $2.83 M(+154.9%) |
| Sept 2015 | - | $760.00 K(+43.3%) | $1.11 M(+9.7%) |
| June 2015 | - | $530.40 K(-427.8%) | $1.01 M(-10.3%) |
| Mar 2015 | - | -$161.80 K(+819.3%) | $1.13 M(-23.2%) |
| Dec 2014 | -$37.40 M(+36.1%) | -$17.60 K(-102.7%) | $1.47 M(+4.1%) |
| Sept 2014 | - | $661.40 K(+2.2%) | $1.41 M(+60.9%) |
| June 2014 | - | $647.20 K(+259.8%) | $878.50 K(>+9900.0%) |
| Mar 2014 | - | $179.90 K(-338.9%) | $5500.00(-97.8%) |
| Dec 2013 | -$27.48 M(-7.6%) | -$75.30 K(-159.4%) | $245.40 K(+92.3%) |
| Sept 2013 | - | $126.70 K(-156.1%) | $127.60 K(-210.5%) |
| June 2013 | - | -$225.80 K(-153.8%) | -$115.50 K(+474.6%) |
| Mar 2013 | - | $419.80 K(-317.4%) | -$20.10 K(-95.2%) |
| Dec 2012 | -$29.74 M(-6.2%) | -$193.10 K(+65.9%) | -$419.20 K(-712.9%) |
| Sept 2012 | - | -$116.40 K(-10.7%) | $68.40 K(-44.6%) |
| June 2012 | - | -$130.40 K(-730.0%) | $123.40 K(-70.0%) |
| Mar 2012 | - | $20.70 K(-93.0%) | $411.20 K(-48.7%) |
| Dec 2011 | -$31.71 M(+37.8%) | $294.50 K(-579.6%) | $801.60 K(+5.5%) |
| Sept 2011 | - | -$61.40 K(-139.0%) | $759.80 K(-21.3%) |
| June 2011 | - | $157.40 K(-61.7%) | $965.90 K(-10.4%) |
| Mar 2011 | - | $411.10 K(+62.7%) | $1.08 M(+59.5%) |
| Dec 2010 | -$23.01 M | $252.70 K(+74.6%) | $675.80 K(+52.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2010 | - | $144.70 K(-46.3%) | $443.40 K(+41.3%) |
| June 2010 | - | $269.70 K(+3000.0%) | $313.70 K(+232.3%) |
| Mar 2010 | - | $8700.00(-57.1%) | $94.40 K(-48.4%) |
| Dec 2009 | -$24.72 M(-57.8%) | $20.30 K(+35.3%) | $182.90 K(+48.7%) |
| Sept 2009 | - | $15.00 K(-70.2%) | $123.00 K(-144.7%) |
| June 2009 | - | $50.40 K(-48.1%) | -$275.40 K(-56.9%) |
| Mar 2009 | - | $97.20 K(-345.5%) | -$638.80 K(-45.0%) |
| Dec 2008 | -$58.52 M(+68.4%) | -$39.60 K(-89.7%) | -$1.16 M(-16.6%) |
| Sept 2008 | - | -$383.40 K(+22.5%) | -$1.39 M(+2.0%) |
| June 2008 | - | -$313.00 K(-26.4%) | -$1.37 M(+30.7%) |
| Mar 2008 | - | -$425.00 K(+56.7%) | -$1.04 M(+95.5%) |
| Dec 2007 | -$34.75 M(+44.2%) | -$271.30 K(-23.9%) | -$534.30 K(-15.3%) |
| Sept 2007 | - | -$356.30 K(-4610.1%) | -$630.90 K(+125.4%) |
| June 2007 | - | $7900.00(-90.7%) | -$279.90 K(+51.3%) |
| Mar 2007 | - | $85.40 K(-123.2%) | -$185.00 K(-27.2%) |
| Dec 2006 | -$24.11 M(+151.6%) | -$367.90 K(+6841.5%) | -$254.20 K(-191.7%) |
| Sept 2006 | - | -$5300.00(-105.2%) | $277.20 K(+6.5%) |
| June 2006 | - | $102.80 K(+534.6%) | $260.40 K(+31.4%) |
| Mar 2006 | - | $16.20 K(-90.1%) | $198.10 K(+410.6%) |
| Dec 2005 | -$9.58 M(+39.3%) | $163.50 K(-839.8%) | $38.80 K(-112.8%) |
| Sept 2005 | - | -$22.10 K(-154.6%) | -$303.90 K(-40.0%) |
| June 2005 | - | $40.50 K(-128.3%) | -$506.90 K(-17.7%) |
| Mar 2005 | - | -$143.10 K(-20.1%) | -$615.60 K(+22.9%) |
| Dec 2004 | -$6.88 M(-31.7%) | -$179.20 K(-20.4%) | -$500.80 K(+56.9%) |
| Sept 2004 | - | -$225.10 K(+230.1%) | -$319.20 K(+68.9%) |
| June 2004 | - | -$68.20 K(+141.0%) | -$189.00 K(+177.1%) |
| Mar 2004 | - | -$28.30 K(-1279.2%) | -$68.20 K(-36.6%) |
| Dec 2003 | -$10.08 M(-22.9%) | $2400.00(-102.5%) | -$107.60 K(-42.3%) |
| Sept 2003 | - | -$94.90 K(-280.4%) | -$186.50 K(+21.2%) |
| June 2003 | - | $52.60 K(-177.7%) | -$153.90 K(+84.3%) |
| Mar 2003 | - | -$67.70 K(-11.5%) | -$83.50 K(-42.6%) |
| Dec 2002 | -$13.06 M(+17.1%) | -$76.50 K(+22.8%) | -$145.40 K(-36.8%) |
| Sept 2002 | - | -$62.30 K(-150.7%) | -$230.10 K(+7.3%) |
| June 2002 | - | $123.00 K(-194.9%) | -$214.50 K(-57.1%) |
| Mar 2002 | - | -$129.60 K(-19.6%) | -$499.70 K(+13.2%) |
| Dec 2001 | -$11.15 M(+32.0%) | -$161.20 K(+245.2%) | -$441.30 K(-19.3%) |
| Sept 2001 | - | -$46.70 K(-71.2%) | -$546.70 K(-4.5%) |
| June 2001 | - | -$162.20 K(+127.8%) | -$572.60 K(+19.8%) |
| Mar 2001 | - | -$71.20 K(-73.3%) | -$477.90 K(-12.2%) |
| Dec 2000 | -$8.45 M(+21.0%) | -$266.60 K(+267.2%) | -$544.40 K(-10.8%) |
| Sept 2000 | - | -$72.60 K(+7.6%) | -$610.40 K(+0.7%) |
| June 2000 | - | -$67.50 K(-51.0%) | -$605.90 K(-10.1%) |
| Mar 2000 | - | -$137.70 K(-58.6%) | -$674.10 K(+11.8%) |
| Dec 1999 | -$6.98 M(+73.3%) | -$332.60 K(+388.4%) | -$602.70 K(-16.3%) |
| Sept 1999 | - | -$68.10 K(-49.8%) | -$719.80 K(-8.0%) |
| June 1999 | - | -$135.70 K(+104.7%) | -$782.70 K(-0.1%) |
| Mar 1999 | - | -$66.30 K(-85.3%) | -$783.10 K(-15.6%) |
| Dec 1998 | -$4.03 M(+260.4%) | -$449.70 K(+243.3%) | -$928.10 K(-58.5%) |
| Sept 1998 | - | -$131.00 K(-3.7%) | -$2.24 M(-29.9%) |
| June 1998 | - | -$136.10 K(-35.6%) | -$3.19 M(-28.0%) |
| Mar 1998 | - | -$211.30 K(-88.0%) | -$4.43 M(-18.7%) |
| Dec 1997 | -$1.12 M(-45.3%) | -$1.76 M(+62.0%) | -$5.45 M(+47.6%) |
| Sept 1997 | - | -$1.09 M(-21.1%) | -$3.69 M(+41.6%) |
| June 1997 | - | -$1.38 M(+11.7%) | -$2.61 M(+111.7%) |
| Mar 1997 | - | -$1.23 M | -$1.23 M |
| Dec 1996 | -$2.04 M | - | - |
FAQ
- What is COSCIENS Biopharma annual earnings before interest & taxes?
- What is the all time high annual EBIT for COSCIENS Biopharma?
- What is COSCIENS Biopharma annual EBIT year-on-year change?
- What is COSCIENS Biopharma quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for COSCIENS Biopharma?
- What is COSCIENS Biopharma quarterly EBIT year-on-year change?
- What is COSCIENS Biopharma TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for COSCIENS Biopharma?
- What is COSCIENS Biopharma TTM EBIT year-on-year change?
What is COSCIENS Biopharma annual earnings before interest & taxes?
The current annual EBIT of CSCI is -$18.01 M
What is the all time high annual EBIT for COSCIENS Biopharma?
COSCIENS Biopharma all-time high annual earnings before interest & taxes is $9.42 M
What is COSCIENS Biopharma annual EBIT year-on-year change?
Over the past year, CSCI annual earnings before interest & taxes has changed by -$2.75 M (-18.06%)
What is COSCIENS Biopharma quarterly earnings before interest & taxes?
The current quarterly EBIT of CSCI is -$5.84 M
What is the all time high quarterly EBIT for COSCIENS Biopharma?
COSCIENS Biopharma all-time high quarterly earnings before interest & taxes is $1.93 M
What is COSCIENS Biopharma quarterly EBIT year-on-year change?
Over the past year, CSCI quarterly earnings before interest & taxes has changed by -$4.88 M (-505.70%)
What is COSCIENS Biopharma TTM earnings before interest & taxes?
The current TTM EBIT of CSCI is -$11.53 M
What is the all time high TTM EBIT for COSCIENS Biopharma?
COSCIENS Biopharma all-time high TTM earnings before interest & taxes is $5.77 M
What is COSCIENS Biopharma TTM EBIT year-on-year change?
Over the past year, CSCI TTM earnings before interest & taxes has changed by -$9.01 M (-356.87%)